Negative screening of Fabry disease in patients with conduction disorders requiring a pacemaker

Ángela López-Sainz 1,2, Vicente Climent 3, Tomas Ripoll-Vera 4, María Angeles Espinosa 2,5, Roberto Barriales-Villa 2,6, Marina Navarro 2,7, Javier Limeres 2,8, Diana Domingo 9, David C. Kasper 10 and Pablo García-Pavia 1,2,11 *

Abstract

Identification of Fabry disease (FD) in cardiac patients has been restricted so far to patients with left ventricular hypertrophy. Conduction problems are frequent in FD and could precede other manifestations, offering a possible earlier diagnosis. We studied the prevalence of FD in 188 patients < 70 years with conduction problems requiring pacemaker implantation. Although classical manifestations of FD were not rare, no patient with FD was identified. Screening efforts should not be conducted in this population.

Keywords: Fabry disease, Conduction disease, Pacemaker, Left ventricular hypertrophy, Screening

Anderson-Fabry disease (AFD) is a rare condition associated with an important diagnostic delay [1]. Contributing factors are the rarity of this disease and the lack of awareness among physicians. Early diagnosis is important in AFD because appropriate therapies seem to be more effective when initiated promptly.

AFD is an X-linked disorder secondary to mutations in the GLA gene, resulting in a deficiency in α-galactosidase A (α-Gal A), which leads to the abnormal accumulation of globotriaosylceramide in affected organs. At the cardiac level, patients with AFD can present with hypertrophic cardiomyopathy, microvascular angina and conduction problems/arrhythmias [2].

Efforts in the identification of AFD in cardiac patients have been restricted to screening of large series of patients with unexplained left ventricular hypertrophy, where AFD has been reported in 1–2% of individuals [3].

Although AFD patients mostly die because of cardiac problems, unexplained left ventricular hypertrophy is present in only one-half of all AFD patients. Moreover, conduction problems and arrhythmias are a frequent problem in patients with AFD and could precede other cardiac manifestations, offering a possible earlier diagnosis. Indeed, the rate of pacemaker insertion (PMI) in AFD has been described to be 25 times higher than in the general population, and the requirement of PMI has been reported to be as high as 8% in some AFD series [4, 5].

With these data, we hypothesized that AFD could be an underdiagnosed entity among patients with unexplained conduction disturbances requiring PMI, and that this group of patients could be an appropriate group to test screening strategies.

We therefore designed a multicenter, cross-sectional study to investigate the prevalence of AFD in patients with unexplained atrioventricular blockade or sinus node disease requiring PMI at < 70 years of age. A total of 188 patients (66% males, mean age 63 ± 9 years) were identified from the existing PMI databases at 8 Spanish hospitals. All patients fulfilling inclusion criteria who underwent PMI between January 2015 and December 2016 were invited to participate. Males were screened by measuring α-Gal A activity and those with reduced levels were genetically tested for GLA mutations. All females were tested for mutations in GLA.

Baseline clinical characteristics of the cohort, stratified by sex, are summarized in Table 1.
Almost one-third of our cohort presented evidence of echocardiographic alterations. Left ventricular hypertrophy on echocardiogram (≥12 mm) was found in 46% of patients. ECG signs compatible with AFD, including prolonged PR interval or left ventricular hypertrophy, were not infrequently reported (30 and 22%, respectively). Regarding other non-cardiac classical findings related to AFD, 17% of the patients showed some degree of renal impairment (defined as a glomerular filtration < 50 mL/min/1.73m²), and 3% reported neuropathic disease. From the 188 patients with conduction problems undergoing PMI screened for AFD, we failed to find any patient with the condition. The mean α-Gal A enzyme activity in males was 3.8 ± 1.7 μmol/L/h, more than threefold higher than the normal cut-off value (1.2 μmol/L/h). A total of 75 individuals (11 males and 64 females) were genetically tested for mutations in the GLA gene. Genetic variants associated with low α-Gal A enzyme activity that are considered to be polymorphisms (e.g., p.D313Y) were present in 1 female but no patient had a pathogenic mutation.

Reasons for the negative results of the AFD screening in this population could include relative younger age and absence of prolonged QRS interval in some of the patients studied. It has been reported that among AFD patients, those older and with longer QRS interval (>110 ms) are at higher risk of requiring antibradycardia pacing [4]. In our cohort, the mean age was 63 years and 48% of patients exhibited a QRS interval < 110 ms.

In conclusion, although our data suggest that classical cardiac manifestations attributed to AFD are not rare in the population requiring PMI, AFD is not a frequent cause of unexplained conduction problems requiring PMI. Therefore, it seems that screening efforts should not be conducted in this patient population.

The appropriate group of patients to whom AFD screening should be performed in the cardiac setting beyond those with unexplained LV hypertrophy ≥15 mm will require further evaluation. Other possible groups of patients with cardiac disease in whom AFD screening would need to be evaluated include patients with mild LVH, those with ECG abnormalities (short PR interval, high voltages and/or inverted T waves) without overt LVH, and those with vasospastic angina.

**Abbreviations**

AFD: Anderson-Fabry Disease; LV: Left ventricular; PMI: Pacemaker insertion; SCD: Sudden cardiac death

**Acknowledgements**

Not applicable.

**Authors’ contributions**

ALS analyzed and interpreted the data, and drafted the manuscript. All authors contributed in the acquisition of the data and critically reviewed the manuscript. PGP designed manuscript content, wrote the manuscript and obtained funding. All authors read and approved the final manuscript.

**Funding**

This work was partially supported by grants from Genzyme-Sanofi (Investigator Initiated Research Grant 2017) and by the Instituto de Salud Carlos III (PI17/01941). Funders played no role in the design, collection, analysis, or interpretation of the data or in the decision to submit the manuscript for publication.

**Availability of data and materials**

Please contact corresponding author for data requests.
Ethics approval and consent to participate
Ethic approval was obtained from Puerta de Hierro Hospital ethics committee. Patients provided written consent.

Consent for publication
Not applicable.

Competing interests
PGP reports consulting fees from Genzyme and Shire; speaking fees from Genzyme, Shire and Amicus; and research funding from Genzyme and Shire. TRV reports consulting fees from Genzyme and Amicus; and speaking fees from Shire and Amicus; RBV reports consulting fees from Genzyme and Amicus; speaking fees from Genzyme and Shire and research funding from Genzyme. Other authors have no conflict of interest relevant to this work to declare.

Author details
1Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Manuel de Falla, 2, Majadahonda, 28222 Madrid, Spain. 2CIBER in Cardiovascular Diseases (CIBERCV), Madrid, Spain. 3Cardiology Department, Hospital General Universitario de Alicante, ISABIAL – FISABIO, Alicante, Spain. 4Cardiology Department, Hospital Universitario Son Llatzer, IdISBa, Mallorca, Spain. 5Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 6Inherited Cardiovascular Diseases Unit, Cardiology Service, Complexo Hospitalario Universitario de A Coruña, Instituto de Investigación Biomédica de A Coruña (INIBIC) Servizo Galego de Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain. 7Department of Cardiology, Hospital Universitario Virgen de Arrixaca, El Palmar, Spain. 8Inherited Cardiovascular Diseases Unit, Department of Cardiology, ValldiHebron University Hospital, Barcelona, Spain. 9Department of Cardiology, Hospital Universitario La Fe, Valencia, Spain. 10ARCHIMED Life Science, Leberstrasse 20, 1110 Vienna, Austria. 11University Francisco de Vitoria (UFV), Pozuelo de Alarcon, Madrid, Spain.

Received: 10 May 2019 Accepted: 25 June 2019
Published online: 08 July 2019

References
1. Reisin R, Perrin A, Garcia-Pavia P. Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pract. 2017;71(1).
2. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;125:16–27.
3. Favalli V, Disabato E, Molinaro M, Tagliani M, Scarabotto A, Serio A, et al. Genetic screening of Anderson-Fabry disease in Probands referred from multispecialty clinics. J Am Coll Cardiol. 2016;68:1037–50.
4. O’Mahony C, Coats C, Cardona M, Garcia A, Calçagnino M, Murphy E, et al. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace. 2011;13:1781–8.
5. Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Dr C, et al. Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol. 2011;57:1093–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.